Ray Dalio Vertex Pharmaceuticals Inc Transaction History

Bridgewater Associates, LP

$17.3 Billion
Q3 2024

A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bridgewater Associates, LP holds 3,452 shares of VRTX stock, worth $1.56 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,452

Previous 33,229 89.61%

Holding current value

$1.56 Million

Previous $15.6 Million 89.7%

% of portfolio

0.01%

Previous 0.08%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$460.0 - $505.78 $13.7 Million - $15.1 Million	-29,777 Reduced 89.61%	3,452 $1.61 Million
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $39.9 Million - $49.3 Million	-101,466 Reduced 75.33%	33,229 $15.6 Million
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $954,402 - $1.04 Million	2,341 Added 1.77%	134,695 $56.3 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $8.92 Million - $10.7 Million	-25,995 Reduced 16.42%	132,354 $53.9 Million
Q3 2023 Nov 13, 2023	SELL	$338.18 - $362.46 $6.08 Million - $6.51 Million	-17,964 Reduced 10.19%	158,349 $55.1 Million
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $8.79 Million - $9.84 Million	-27,963 Reduced 13.69%	176,313 $62 Million
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $29.3 Million - $33.4 Million	103,457 Added 102.62%	204,276 $64.4 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $18.1 Million - $20.3 Million	-63,172 Reduced 38.52%	100,819 $29.1 Million
Q3 2022 Nov 10, 2022	SELL	$273.83 - $305.53 $14.6 Million - $16.2 Million	-53,161 Reduced 24.48%	163,991 $47.5 Million
Q2 2022 Aug 11, 2022	BUY	$234.96 - $292.55 $43.9 Million - $54.7 Million	187,000 Added 620.19%	217,152 $61.2 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $3.93 Million - $4.63 Million	17,735 Added 142.83%	30,152 $7.87 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $477,927 - $603,315	-2,700 Reduced 17.86%	12,417 $2.73 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $1.48 Million - $1.65 Million	-8,139 Reduced 35.0%	15,117 $2.74 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $293,796 - $346,463	1,567 Added 7.22%	23,256 $4.69 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $3.74 Million - $4.36 Million	18,059 Added 497.49%	21,689 $4.66 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $751,446 - $1 Million	3,630 New	3,630 $858,000
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $5.38 Million - $7.22 Million	-32,260 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$166.23 - $187.09 $5.36 Million - $6.04 Million	32,260 New	32,260 $5.47 Million
Q2 2019 Aug 13, 2019	SELL	$164.61 - $190.37 $3.6 Million - $4.17 Million	-21,889 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $3.58 Million - $4.26 Million	21,889 New	21,889 $4.03 Million
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $2.6 Million - $2.99 Million	-15,509 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$145.72 - $169.96 $2.26 Million - $2.64 Million	15,509 New	15,509 $0

Others Institutions Holding VRTX

# of Institutions

1,721

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track Ray Dalio's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Account